Written questions by Shelbrooke.

What consultation has his Department undertaken with vending and automated retailing businesses and other relevant stakeholders before proposing restrictions on the sale of high-energy caffeine drinks.

The Department engaged with relevant stakeholders, including representatives of the vending and automated retail sector, prior to publishing its proposals for banning the sale of high-caffeine energy drinks.Building on initial engagements, the Department ran a 12 week consultation, which was open from 3 September 2025 to 26 November 2025. This formal consultation invited views from all interested parties, including businesses operating in the vending and automated retailing sectors, on the proposed age restriction and its implementation.The Department is currently reviewing all consultation submissions and will set out a formal consultation response in due course.

What steps his Department is taking to implement a sustainable funding model for independent adult hospices.

We have provided a £125 million capital funding boost for eligible adult, and children and young people’s, hospices in England to ensure they have the best physical environment for care.The Government is developing a Palliative Care and End-of-Life Care Modern Service Framework (MSF) for England. We will consider contracting and commissioning arrangements as part of our MSF. We recognise that there is currently a mix of contracting models in the hospice sector. By supporting integrated care boards (ICBs) to commission more strategically, we can move away from grant and block contract models. In the long term, this will aid sustainability and help hospices’ ability to plan ahead.Officials are working closely with a number of stakeholders from the hospice sector in the development of the MSF.Additionally, the recently published Medium-Term Planning Guidance and the Model ICB Blueprint set out that ICBs should act as strategic commissioners with core functions including: understanding current and projected total service utilisation and costs; identifying underserved communities; assessing quality, performance, and productivity of existing provision; and significantly reducing avoidable unplanned hospital admissions.

Whether his Department made an assessment of trends in the levels of current waiting times for cancer treatment in NHS Humber and North Yorkshire and NHS West Yorkshire sub-ICBs prior to funding decisions for the forthcoming National Cancer Plan.

Cancer patients are waiting too long for diagnosis and treatment on the National Health Service, including in Humber and North Yorkshire and NHS West Yorkshire. The Government is investing an extra £26 billion in the NHS and opening up community diagnostic centres at evening and weekends, to help diagnose cancer earlier.We have also invested £70 million of funding into new radiotherapy treatment machines to replace older, less efficient machines. These new machines are currently being rolled out to trusts throughout the country. These newer machines will reduce treatment times, boost productivity, and allow more patients to be seen over the same period.The National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately drive up this country’s cancer survival rates.

Who has been selected to represent (a) midwifery, (b) obstetrics and (c) neonatal care for his Independent Maternity and Neonatal Investigation.

The list of Expert Advisers supporting Baroness Amos is published in the terms of reference. They include:a) Professor Julia Sanders and Lesley Sharkey, both midwives.b) Professor Alex Heazell and Dr Christine Ekechi, both obstetricians.c) Dr Edile Murdoch and Dr Alison Bedford-Russell, both neonatologists.

If his Department will publish (a) the long list of NHS trusts considered by the Chair for inclusion in the Independent Maternity and Neonatal Investigation and (b) the selection criteria used by the Investigation team to assess those trusts.

The 14 NHS trusts to be looked at as part of the independent National Maternity and Neonatal Investigation were announced on 15 September 2025. There are no plans to publish the long list of NHS trusts considered by the chair for inclusion in the investigation.The 14 NHS trusts were selected by the independent investigation based on a variety of factors, including results from the Care Quality Commission’s Maternity Patient Survey and Mothers and Babies: Reducing Risk through Audits and Confidential Enquiries across the UK’s perinatal mortality rates, in addition to variation in case mix, trust type, geographic coverage, provision of care to individuals from diverse backgrounds, and family feedback.Three of the trusts have been included due to their inclusion in previous investigations or reviews, these three trusts being the Shrewsbury and Telford Hospital NHS Trust, the East Kent Hospitals University NHS Foundation Trust, and the University Hospitals of Morecambe Bay NHS Foundation Trust.

What steps his Department is taking to improve access to Dienogest for people with endometriosis.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based guidance for the National Health Service in England on best practice. In its guideline on the diagnosis and management of endometriosis, last updated in November 2024, NICE recommends that hormonal treatment such as Dienogest should be offered to women with suspected, confirmed or recurrent endometriosis.It is the clinician’s responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Prescribers must always satisfy themselves that the medicines they consider appropriate for their patients can be safely prescribed and ensure that they take account of NICE guidelines, as well as the local commissioning decisions of their respective integrated care boards.

What steps his Department is taking to improve (a) awareness of, (b) diagnosis of and (c) access to effective treatment within the NHS for those affected by Premenstrual Dysphoric Disorder.

The Government is committed to prioritising women’s health as we reform the National Health Service. We recognise that Premenstrual Dysphoric Disorder (PMDD) is a serious condition which can be both distressing and disabling for those that experience PMDD symptoms.The Department and the NHS have created a women’s health area on the NHS website, which brings together over 100 health topics including periods, gynaecological conditions, fertility, pregnancy, heart health and cancers, and is designed to be a first port of call for women seeking health information. The page on premenstrual syndrome contains information and advice on PMDD.Women’s health hubs have a key role in shifting care out of hospitals and improving care for women’s health conditions. As of December 2024, 39 out of 42 integrated care boards (ICBs) reported to NHS England that they had at least one operational women’s health hub. We continue to engage with and encourage ICBs to use the learning from the women’s health hubs pilots to improve local delivery of services to women.Psychological support is also available to women experiencing premenstrual dysphoric disorder through local NHS Talking Therapies services, which provide evidence-based treatments, such as cognitive behavioural therapy, for common mental health conditions including depression and anxiety. People can self-refer to NHS Talking Therapies services or be referred by their general practitioner.